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Abstract DNA chip technology was used in an attempt to
identify target genes responsible for apoptosis induced by
etoposide, a p53 activating topoisomerase II inhibitor used
clinically as an antitumor agent. 62 Individual mRNAs whose
mass changed significantly were identified after screening
oligonucleotide arrays capable of detecting 6591 unique human
mRNA species. 12 (Nine induced and three repressed) of the
etoposide-responsive genes were further studied by Northern
analysis and an agreement rate of 92% was reached. Among the
12 genes studied, two (WAF1/p21 and PCNA) are known p53
regulatory genes, two (glutathione peroxidase and S100A2
calcium-binding protein) appear to be the novel p53 target genes
and the others appear to be p53-independent. Based upon these
findings, the signalling pathways that possibly mediate etoposide-
induced apoptosis are proposed.
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1. Introduction
Etoposide (VP16) is a DNA topoisomerase II inhibitor [1].
It has been shown to be active against a variety of tumor cells
in both preclinical and clinical studies [2]. Etoposide is used as
an antitumor agent in clinic, mainly for the treatment of tes-
ticular cancers and small cell lung carcinomas [2,3]. The main
toxicity derived from the use of etoposide is bone marrow
depression with leucopenia and thrombocytopenia. Other
side e¡ects include nausea, diarrhea, mucositis, and hypoten-
sion [2,3]. As a DNA damaging reagent, etoposide has been
shown to induce apoptosis in a variety of tumor cell lines
harboring either wild-type or mutant p53 [4,5]. Although the
entire signalling pathways mediating etoposide-induced apop-
tosis are not clear, one pathway could involve p53, since DNA
damage induced by etoposide has been shown to activate the
p53 activity [6].
In an attempt to identify the genes responsive to or respon-
sible for etoposide-induced apoptosis and to reveal the apop-
tosis signalling pathways triggered by a DNA damaging re-
agent, we have utilized the DNA chip technology to
simultaneously display changes of gene expression. A set of
four oligonucleotide arrays, representing 6591 known genes,
was screened. Among the 12 genes characterized, some are
previously known as p53-responsive genes, while others are
the novel p53 target genes and still others are involved in
p53-independent signalling pathways. Characterization of
these etoposide-responsive genes may lead to the identi¢cation
of novel target(s) for the discovery of anticancer drugs.
2. Materials and methods
2.1. Cell cultures
U2-OS cells, a human osteogenic sarcoma cell line with endogenous
wild-type p53, were grown in 10% McCoy’s 5A medium. For drug
treatment, subcon£uent cells were incubated with etoposide (25 or 50
WM, Sigma) for 6 or 24 h. The control cells were treated with DMSO
for 24 h.
2.2. cDNA probe preparations
cDNAs encoding Waf-1 [7], GPX (a gift from Dr. Larry Oberley at
the University of Iowa) were used as probes. The following probes
were generated by RT-PCR as described [8] using human placenta
RNA (Oncor) as the template: calcyclin/S100A6, proliferating cell
nuclear antigen (PCNA), ornithine carboxylase (ODC), heterogeneous
nuclear ribonucleoprotein core protein A1 (HnRNP), metallothionein-
II (MT-2), S100 calcium-binding protein A2 (S100A2), transforming
growth factor-L type II receptor (TGFL-RII) and thioredoxin (TXN).
The primers were designed based upon the published sequence (see
Table 1), £anking the entire open reading frame. A single PCR frag-
ment with expected size was gel-puri¢ed. Some of them were sub-
cloned and sequenced. Tubulin L-1 chain (accession #: T65580) and
ferritin light chain (accession #: T72863) were obtained from the
Washington University/Merck EST bank. The clones were PCR am-
pli¢ed and sequenced. The housekeeping gene, glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), was obtained from Ambion.
2.3. Northern analysis
Total RNA was isolated from etoposide-treated cells using RNAzol
solution (Tel-Test). 15 Wg of total RNA or 1.8 Wg of poly (A+) RNA
was subjected to Northern analysis as previously described [9]. Den-
sitometric quantitation was performed on a densitometer (Molecular
Dynamics) or on a phosphoimager (STORM 860 Molecular Dynam-
ics).
2.4. DNA chip technology
A¡ymetrix oligonucleotide arrays were used for mRNA expression
pro¢ling [10,11]. Polyadenylated RNA was isolated from 5U107 lysed
cells using Qiagen Oligotex. Double stranded cDNA was prepared in
20 Wl volumes using Life Technologies Superscript Choice System and
an oligo-(dT)24 anchored T7 primer [10]. The ¢nal reaction conditions
for the ¢rst strand synthesis were 50 mM Tris-HCl, pH 8.3, 75 mM
KCl, 3 mM MgCl2, 10 mM DTT, 500 Wm of each of dATP, dCTP,
dGTP, dTTP, 100 pmol primer, 0.1^5 Wg of mRNA and 200 U Super-
script II reverse transcriptase/Wg mRNA, 1 h at 37‡C. Second strand
synthesis was carried out for 2 h at 16‡C in 150 Wl volumes containing
25 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl2, 10 mM
(NH4)2SO4, 0.15 mM L-NAD, 250 Wm of each of dATP, dCTP,
dGTP, dTTP, 1.2 mM DTT, 65 U/ml DNA ligase, 250 U/ml DNA
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polymerase I, 13 U/ml RNase H followed by 5 min at 16‡C with 67 U/
ml T4 DNA polymerase. The cDNA synthesis was terminated by the
addition of 10 Wl of 0.5 M EDTA. Double stranded cDNA products
were puri¢ed by phenol:chloroform:isoamyl alcohol (25:24:1 satu-
rated with 10 mM Tris-HCl, pH 8.0/1 mM EDTA) extraction, phase
separation using Phase Lock Gels (PLG1, 5P-3P) and ethanol precip-
itation. Biotinylated RNA was synthesized using an Ambion T7
Megascript system with biotin-11-CTP and biotin-16-UTP (7.5 mM
ATP, 7.5 mM GTP, 5.625 mM unlabelled UTP, 1.875 mM bio-UTP,
5.625 mM unlabelled CTP, 1.875 mM bio-CTP) for 4 h at 37‡C. In
vitro transcription products (IVT) were puri¢ed using Qiagen
RNAeasy columns. Biotinylated RNA products were fragmented for
35 min at 94‡C in a bu¡er composed of 200 mM Tris acetate, pH 8.1,
500 mM potassium acetate, 150 mM magnesium acetate. A¡ymetrix
GeneChip arrays (HUM6000) were hybridized with the biotinylated
IVT products (10 Wg/chip) for 16 h at 40‡C. using the manufacturer’s
hybridization bu¡er. After washing the arrays, hybridized RNA was
detected using streptavidin-phycoerythrin staining (6USSPE, 0.05%
Triton X-100, pH 7.6, 1 mg/ml acetylated bovine serum albumin,
2 Wg/ml streptavidin-phycoerythrin from Molecular Probes) for
10 min at 40‡C. The DNA chips were scanned using a specially de-
signed confocal scanner made for A¡ymetrix by Hewlett-Packard
(commercially available through A¡ymetrix, Santa Clara, CA,
USA). The excitation source was an argon ion laser and the emission
was detected by a photomultiplier tube through a 570 nm longpass
¢lter. Digitized image data were processed using the GeneChip soft-
ware (version 3.0) from A¡ymetrix as described previously [10]. RNA
abundance was determined based on the average of the di¡erences
between perfect match and mismatch intensities for each probe family.
Gene induction or repression was considered signi¢cant if the change
in average di¡erence intensity was above 2-fold [12].
3. Results
3.1. Identi¢cation of the genes responsive to apoptosis induced
by etoposide: the use of DNA chip technology
We have previously shown that etoposide, a topoisomerase
II inhibitor, induces p53 DNA-binding and transactivation in
U2-OS, a human osteogenic sarcoma cell line harboring wild-
type p53 [6]. We have also observed that after etoposide treat-
ment, cells undergo apoptosis as revealed by morphological
changes such as cell shrinkage and detachment and by DNA
fragmentation (data not shown). In an attempt to identify
genes whose expression changed during etoposide-induced
apoptosis, we utilized DNA chip technology to obtain an
overall pro¢le of gene expression. Since etoposide induces
apoptosis in both p53 positive and p53 negative cells [4,5],
both p53-responsive and non-responsive genes are expected
to be identi¢ed. In order to identify both early and late apop-
tosis-responsive genes, poly (A+) mRNA was isolated from
cells treated with etoposide (25 WM) for 6 h (neither obvious
morphological change, nor DNA fragmentation) and for 24 h
(obvious morphological signs of apoptosis/DNA fragmenta-
tion) and subjected to oligonucleotide chip hybridization.
Cells treated with DMSO for 24 h were used as the control.
A total of four chips, containing 6591 genes were screened.
The hybridization results from all four chips were compiled
and sorted on the basis of fold change compared to control
cells. Genes that displayed approximately two-fold or greater
changes were scored as signi¢cant changes [12]. 62 mRNA
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Table 1
Primers used for the generation of cDNA probes by RT-PCR
Genes Primers Expected size References
Calcyclin/S100A6 Cal-01, 5P-ATGGCATGCCCCCTGGATC-3P 270 bp Accession # J02763
Cal-02, 5P-TCAGCCCTTGAGGGCTTCAT-3P
HnRNP HnRNP-01A, 5P-GCCGTCATGTCTAAGTCAGA-3P 960 bp Accession # X12671
HnRNP-02, 5P-TTAAAATCTTCTGCCACTGCC-3
MT-2 MT-01, 5P-GGAATTCGCCGCCATGGATCCCAACTGC-3P 212 bp Accession # J00271
MT-02, 5P-GGAATTCCCAGCATCAGGCGCAGC-3P
ODC ODC-01, 5P-GGAATTCATGAACAACTTTGGTAAT-3P 1437 bp [28]
ODC-02, 5P-GGAATTCAAGCTAAACTTGCAGTT-3P
PCNA PCNA-01, 5P-GGAATTCCCGCCTGCCTGTAG-3P 855 bp [29]
PCNA-02, 5P-GGAATTCTTGAATTTTAAGAATGCC-3P
S100A2 S100A2-01, 5P-ATGTGCAGTTCTCTGGAGCA-3P 294 bp Accession # Y07755
S100A2-02, 5P-TCAGGGTCGGTCTGGGCA-3P
TGFL-RII TGFR-01, 5P-ATGGGTCGGGGGCTGCTC-3P 1.7 kb Accession # M85079
TGFR-02, 5P-GCTATTTGGTAGTGTTTAGGG-3P
TXN TXN-11, 5P-GGAATTCGCCAAGATGGTGAAGCA-3P 348 bp [30]
TXN-12, 5P-GGAATTCAGAAAACATGATTAGAC-3P
Fig. 1. Induction of Waf-1/p21, PCNA, GPX and ODC by etopo-
side. Subcon£uent U2-OS cells were treated with etoposide (25 WM)
for 6 h or 24 h. Poly (A+) mRNA was isolated and either subjected
to chip hybridization (Table 2) or Northern analysis (1.8 Wg). The
top panel is the expression of mRNA encoding Waf-1/p21, PCNA,
GPX and ODC, as indicated. The bottom panel is the fold induc-
tion of expression after normalization with GAPDH for each indi-
vidual gene. Quantitation was performed on a densitometer.
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species out of the 6591 genes were identi¢ed by these criteria.
Of these 62 mRNA species 41 were signi¢cantly induced and
21 were signi¢cantly repressed at either or both of the time
points (data not shown). Based upon potential involvement in
apoptosis signalling pathways, 12 genes (nine induced and
three repressed) were selected for further analysis and charac-
terization (see Table 2).
3.2. Con¢rmation of etoposide-inducible genes by Northern
analysis
To con¢rm the results obtained from the chip hybridiza-
tion, we used the same batch of mRNA and performed
Northern analysis in a subset of etoposide-inducible genes.
These include Waf-1/p21 and PCNA, two known p53 regula-
tory genes [13,14], and GPX and ODC, two genes unknown
for p53 regulation. GPX is a primary antioxidant enzyme to
decompose hydrogen peroxide, thus preventing oxidative
stress-induced damage [15], whereas ODC is a rate-limiting
enzyme for polyamine biosynthesis, and required for G1 pro-
gression [16]. As shown in Fig. 1 (top), all four genes are
indeed induced by etoposide at both 6 h and 24 h. The fold
induction after normalization with the housekeeping gene,
GAPDH, is shown at the bottom of the ¢gure. A greater
fold induction is observed using Northern analysis, compared
to the chip hybridization (Table 2). This may re£ect more
stringent hybridization conditions used for chip hybridization.
The threshold we set for inclusion as etoposide regulatory
genes is, therefore, valid in this subset of genes examined.
We next performed Northern analysis to further con¢rm
the chip results in a larger set of etopside-responsive genes
detected by the chip assay. We chose eight additional genes
whose expression as detected by chip was either induced (¢ve
out of eight) or repressed (three out of eight) by etoposide
treatment. As shown in Fig. 2 and Table 2, expression pat-
terns for seven out of eight genes correlate with the chip
results. The only disagreement is seen in the gene encoding
thioredoxin in which Northern does not show a signi¢cant
induction. Overall, 20% (12 out of 62) of etoposide-reponsive
genes detected by the chip were examined with Northern anal-
ysis and one false positive was found (Table 2).
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Fig. 2. Validation of the chip results by Northern analysis. Total RNA was isolated from U2-OS cells treated with etoposide (25 WM) for 6
and 24 h and subjected (15 Wg) to Northern analysis. Due to the low abundance of TGFL-RII transcript in U2-OS cells, 1.8 Wg poly(A+)
RNA (the same batch used for chip hybridization) was loaded for Northern analysis. Northern blots were ¢rst hybridized with the indicated
cDNA probes and then with GAPDH. The blots were exposed in a phosphoimager, quantitated against GAPDH and expressed as fold
changes.
Table 2
Comparison of expression changes detected by chips and Northern
in U2OS cells treated by etoposide
Gene DNA Chip Northern
6 h 24 h Di¡ Call 6 h 24 h Di¡ Call
Calcyclin ND 2.4 I 1.5 4.3 I
Ferritin LC 0.1 ND D 0.8 0.1 D
GPX 1.8 2.7 I 5 10 I
hnRNP 1 0.5 0.4 D 0.6 0.7 D
MT-2 2.3 2.7 I 1.1 1.7 I
ODC ND 1.9 I 3 4 I
PCNA 2.5 ND I 3 3 I
S100 A2 ND 2.2 I 1.5 3 I
TGFL-RII ND 2.3 I 0.8 3.6 I
TubulinL1 ND 0.3 D 0.6 0.5 D
TXN 1.8 ND I 1 1.3 NC
WAF-1 1.1 2.4 I 7 17 I
Di¡ Call, Di¡erence Call; I, Increased; D, Decreased; NC, No
Change; ND, Not detected.
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3.3. Identi¢cation of potential novel p53-dependent genes
up-regulated during etoposide-induced apoptosis
Among etoposide-inducible genes, we expect to identify
both p53-responsive and non-responsive genes. We, therefore,
searched for the consensus sequence of the p53 binding site in
the promoter or intron regions of all 41 etoposide-inducible
genes. We allowed two mismatches to the consensus p53 bind-
ing sequence but no spacer between the two 10 bp motifs,
since almost all endogenous p53 target genes have a few mis-
matches but no spacer [17]. Based upon the available pro-
moter/intron sequences deposited in the GenBank, we identi-
¢ed, as listed in Table 3, putative p53 binding sites in the
promoter of the genes encoding the following proteins: calcy-
clin/S100A6 (a growth regulated, calcium-binding protein)
[18], GPX, S100A2 (a calcium-binding protein) [19] and
TXN, a redox sensitive protein [20], and also in the ¢rst intron
of the gene encoding ODC. None of the ¢ve genes was pre-
viously known as a p53 target gene. Through extensive anal-
yses including a gel shift assay (for speci¢c p53-binding), a
transactivation assay (for p53-dependent target gene activa-
tion) and Northern analysis (for p53-dependent induction of
endogenous target genes by etoposide), we concluded that
GPX and S100A2 are novel p53 target genes [21,22].
3.4. Comparison of p53 regulatory genes identi¢ed by both chip
and series analysis of gene expression (SAGE)
technologies
SAGE technology which can be used to identify both
known and unknown genes [23] has been recently utilized to
identify genes responsible for p53-induced apoptosis [24]. A
total of 65 p53-responsive genes (32 were induced and 33 were
repressed) was identi¢ed after sequencing 101 694 tags, repre-
senting 7202 unique transcripts [24]. 32 Out of these 65 genes,
but none of 13 p53-induced genes (PIGs) [24] were found
among the 6591 genes on the DNA chips. To examine
whether two techniques can identify the same set of the re-
sponsive genes, we compared the 32 p53-responsive genes by
SAGE and 62 etoposide-responsive genes by chip hybridiza-
tion. Although apoptosis inducers (etoposide versus adenovi-
rus-p53) and cell lines (U2-OS versus DLD-1) used in the two
experiments were di¡erent, we are able to ¢nd six (three in-
ducible and three repressed) identical genes picked up by both
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Table 3
Identi¢cation of putative p53 binding sites in the etoposide-inducible genes1
Gene Name Accession p53 binding site sequence Location
Consensus p53 binding site RRRCWWGYYYRRRCWWGYYY2 Promoter or intron
CDK-inhibitor p21 (WAF1) U50603 GAACATGTCCAACATGTTG Promoter
PCNA J05614 ACATATGCCCGGACTTGTTC Promoter
Calcyclin/S100A6 J02763 GGGCTTGGCCGAGCTGGCCT Promoter
Glutathione peroxidase (GPX) Y00483 GGGCCAGACCAGACATGCCT Promoter
Ornithine decarboxylase (ODC) M81740 AAGTTTGTTTGAATTAGCCC Intron 1
S100 calcium-binding protein A2 Y07755 GGGCATGTGTGGGCACGTTC Promoter
Thioredoxin X70286 AGACTTGCCTAGAGTTACCC Promoter
1No space between the two 10 bp motifs and allow two mismatches.
2R: A or G, W: A or T, Y: C or T.
Fig. 3. Signalling pathways that mediate etoposide-induced apoptosis. DNA damage induced by etoposide activates p53 and triggers the p53
signalling pathway which in turn activates the antioxidant pathway as well as the calcium signalling pathway. On the other hand, DNA dam-
age also triggers the polyamine pathway by inducing ODC expression and the TGFL signalling pathway by inducing expression of the TGFL
type II receptor. All these signal transduction pathways converge and apoptosis results.
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technologies (Table 4). This indicates that the two technolo-
gies with di¡erent methodological approaches, can identify
the same set of genes subjected to p53 regulation.
4. Discussion
4.1. Application of DNA chip technology in the detection of
etoposide-responsive genes
To understand the signal transduction pathways leading to
apoptosis induced by etoposide, an anticancer drug used in
clinic, we utilized DNA chip technology to determine the
changes of the gene expression pro¢le. Exposure of cells to
etoposide initiates a complex set of cellular responses as re-
£ected by a global change of gene expression. Among the
6591 genes screened, we have identi¢ed 62 genes (either being
induced or repressed) responsive to etoposide-induced apop-
tosis. Some changes may confer the cellular defense against
DNA damage, while others may potentiate the damage when
repair becomes impossible. Among these 62 genes, we charac-
terized 12 genes by Northern analysis. Although the fold
changes were di¡erent between the two methods, which varied
by a number of factors including stringency of hybridization,
variations in sample preparations, di¡erent ways in normal-
ization for sample loading and so on, an agreement of 92%
was reached. This provides the assurance that the DNA chip
technology can be used as a rapid tool with a high accuracy to
examine global changes of gene expression upon a particular
stimulus.
4.2. Classi¢cation of the etoposide-responsive genes
Among the 12 genes analyzed by Northern, eight genes are
induced, three are repressed and one has no change by etopo-
side. Among the inducible genes, two (Waf-1 and PCNA) are
previously known as p53 downstream targets and two (GPX
and S100A2) appear to be novel p53 regulatory genes [21,22].
Induction of ODC, TGFL-RII and MT-2 appears to be p53-
independent or secondary e¡ects of the p53-induction. Among
the etoposide-repressed genes, HnRNP1 and tubulin L1 could
be subjected to p53 regulation, since they are also repressed in
a p53-induced apoptosis model detected by SAGE technology
[24]. Since p53 inhibits the transcription of several cellular and
viral promoters that lack a p53 binding site [25], more exten-
sive work is needed to identify those subjected to p53 down-
regulation.
4.3. Potential signalling pathways mediating etoposide-induced
apoptosis
Based upon results obtained from this study, we propose
here the potential signalling pathways that could mediate eto-
poside-induced apoptosis. As shown in Fig. 3, DNA damage
induced by etoposide activates p53 which, in turn, transacti-
vates Waf-1/p21, PCNA, GPX and S100A2 to initiate p53-
dependent signalling pathways. In addition, induction of
ODC and TGFL-RII, two genes that have been shown to
mediate apoptosis [26,27], would initiate polyamine and
TGFL signalling pathways, respectively. All these signalling
pathways converge and ultimately lead to apoptosis, although
many details in each pathway need to be worked out. It is
clear that the chip technology can contribute signi¢cantly to
our understanding of the complex cell responses to various
stimuli. Once identi¢ed, such information allows for testing
of more rigorous hypotheses and suggests pursuit of increas-
ingly focused experimental strategies. The ultimate identi¢ca-
tion of patterns of responsive genes for any given treatment of
interest will have a profound in£uence in the target identi¢-
cation and validation in future drug discovery.
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